ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ニザチジン

Nizatidine

HCID 4513
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
76963-41-2
標準SMILES
CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
InChIKey
SGXXNSQHWDMGGP-UHFFFAOYSA-N
分子式
C12H21N5O2S2
平均分子量
331.5 g/mol
単同位体質量
331.11366728

概要

A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

名称と識別子

優先名称
Nizatidine
IUPAC
1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
現地名
ニザチジン
英語名
Nizatidine
分子式
C12H21N5O2S2
分子量
331.46

名称と別名

AcinonNizatidinaAxidAxid ArNizatidinumDTXSID5023376P41PML4GHRLY 139037NSC-7592891,1-Ethenediamine, N-(2-(((2-((dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-LY-139037N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin
名称をさらに表示
N-[2-(2-ジメチルアミノメチル-4-チアゾリルメチルチオ)エチル]-N'-メチル-2-ニトロビニリデンジアミンニザチジンドルセンチザノンアシノンニザチンニザノンニザトリックニザメルクアテミノンN-[2-[[[2-[(ジメチルアミノ)メチル]-4-チアゾリル]メチル]チオ]エチル]-N'-メチル-2-ニトロ-1,1-エテンジアミンN-[2-[2-(ジメチルアミノメチル)-4-チアゾリルメチルチオ]エチル]-N'-メチル-2-ニトロエテン-1,1-ジアミンニザチジン (JP17)N-[2-[2-(ジメチルアミノメチル)-4-チアゾリルメチルチオ]エチル]-N′-メチル-2-ニトロエテン-1,1-ジアミンジメチル[(4-{[(2-{[1-(メチルアミノ)-2-ニトロエテニル]アミノ}エチル)スルファニル]メチル}-1,3-チアゾール-2-イル)メチル]アミンN-[2-(2-ジメチルアミノメチル-4-チアゾリルメチルチオ)エチル]-N′-メチル-2-ニトロビニリデンジアミンN-[2-[[[2-[(ジメチルアミノ)メチル]-4-チアゾリル]メチル]チオ]エチル]-N′-メチル-2-ニトロ-1,1-エテンジアミンnizaxze-101NizaxiZL-101gastraxnizaxidzanizalTizanon
N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamineCHEBI:7601DTXCID403376Zinga 150Zinga 300LY139037RefChem:55724A02BA04

物性

構造計算による物性補完中

XLogP
1.6
極性表面積
140 Ų
水素結合供与体数
2
水素結合受容体数
8
回転可能結合数
9
重原子数
21
形式電荷
0
複雑度
349

実験および物理化学的性質

Chemical ClassesPharmaceutical
OdorMild, sulfur-like odor
TasteBitter
Color/Form · 2 件

Crystals from ethanol-ethyl acetate

Off-white to buff crystalline solid

Solubility · 2 件

10-33mg/mL

Soluble in water

Human Drugs · 3 件

Breast Feeding; Lactation; Anti-Ulcer Agents; Histamine H2 Antagonists; Gastrointestinal Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 件

130-132 °C

130-132 °C

Collision Cross Section178.1 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID5023376]

物理化学的性質

融点
130 · 130-1320C

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (97.6%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.

危険有害性情報

Other Safety InformationIMAP assessments - 1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-: Environment tier I assessment
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesAcute Tox. 4 (97.6%)

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

Concurrent use /of antacids/ with histamine H2-receptor antagonists in the treatment of peptic ulcer may be indicated for the relief of pain; however, simultaneous administration of antacids of medium to high potency (80 mmol to 150 mmol HCl) is not recommended since absorption of histamine H2-receptor antagonists may be decreased; patients should be advised not to take any antacids within 1/2 to 1 hour of histamine H2-receptor antagonists. /Histamine H2-receptor antagonists/

化学と産業

薬理情報

ATC Code · 2 件

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein Binding35%
Pharmacodynamics · 1 件

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.

Mechanism of Action · 1 件

Nizatidine competes with histamine for binding at the H<sub>2</sub>-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.

Biological Half-Life · 2 件

1-2 hours

Half life is 10 hours.

Metabolism/Metabolites · 2 件

Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).

Nizatidine is metabolized in the liver to N-desmethylnizatidine, nizatidine N-oxide, and nizatidine sulfoxide. Of these metabolites, only N-desmethylnizatidine has histamine H2-receptor blocking activity; studies in animals indicate that this metabolite is approximately 60% as active as nizatidine in blocking gastric acid secretion. Orally administered nizatidine undergoes minimal metabolism on first pass through the liver.

FDA Pharmacological Classification

関連反応

2 件
反応記録を作成
HRID 279939 の反応式
HRID 279939生成物として
HRID 1548466 の反応式
HRID 1548466生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
76963-41-2
PubChem CID
4513
DTXSID
DTXSID5023376
ChEMBL
CHEMBL3183075
UNII
P41PML4GHR
EC Number
627-310-4
沸点
478.2 · 478.2±45.0 °C(Predicted)
比重(密度)
1.249 · 1.249±0.06 g/cm3(Predicted)
貯蔵温度
Keep in dark place,Inert atmosphere,Room temperature
溶解性
水に溶けにくく、メタノールに溶ける。
酸解離定数(Pka)
2.1 · 2.1, 6.8(at 25℃)
外見
Solid
色
オフホワイトからペールイエロー
水溶解度
21.4 g/L · 21.4g/L(温度表記なし)
Merck
14 · 14,6660
InChI
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3
InChIKey
SGXXNSQHWDMGGP-UHFFFAOYSA-N
SMILES
C(NCCSCC1=CSC(CN(C)C)=N1)(NC)=C[N+]([O-])=O
CAS データベース
76963 · 76963-41-2(CAS DataBase Reference)

化学的性質

化学的特性White Crystalline Powder

Concurrent use /of bone marrow depressants/ with H2-receptor antagonists may increase the risk of neutropenia or other blood dyscrasias. /Histamine H2-receptor antagonists/

Histamine H2-receptor antagonists may increase gastrointestinal pH; concurrent administration of ketoconazole with histamine H2-receptor antagonists may result in a marked reduction in absorption of ketoconazole; patients should be advised to take histamine H2-receptor antagonists at least 2 hours after ketoconazole. /Histamine H2-receptor antagonists/

Although a decrease in absorption is only reported in the literature for cimetidine and ranitidine, concurrent use with sucralfate may decrease the absorption of any H2-receptor antagonist; patients should be advised to take an H2-receptor antagonist 2 hours before sucralfate. /Histamine H2-receptor antagonists/

No drug interactions were reported when nizatidine and theophylline, lidocaine, warfarin, chlordiazepoxide, diazepam, or lorazepam were used together.

Hepatotoxicity · 1 件

Chronic therapy with nizatidine and other H2 blockers is associated with minor elevations in serum aminotransferase levels in 1% to 4% of patients, but similar rates have been reported in placebo recipients. The ALT elevations are usually asymptomatic and transient and may resolve without dose modification. Rare instances of clinically apparent liver injury have been reported in patients receiving nizatidine, but too few cases have been reported to characterize a typical time to onset or pattern of injury. More information is available on the hepatotoxicity of other H2 blockers such as ranitidine and cimetidine which have been implicated in causing clinically apparent liver injury in 1:20,000 to 1:100,000 users. The time to onset of H2 blocker induced liver injury tends to be short, between 1 and 6 weeks of starting. The typical pattern of serum enzyme elevations varies from hepatocellular to cholestatic, most cases being “mixed”. The injury can be severe, but is typically mild-to- moderate in severity and self-limited in course, resolving within 4 to 12 weeks of stopping. Immunoallergic features (rash, fever, eosinophilia) are uncommon, as is autoantibody formation. Liver biopsy histology often shows centrolobular (zone 3) necrosis with mixed cellular infiltrates and mild cholestasis.

Human Toxicity ExcerptsNizatidine may inhibit alcohol dehydrogenase in the gastric mucosa and produce higher serum levels of alcohol, but this does not appear to be clinically significant.
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Nizatidine

vLess-DILI-concern

5

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 5 件

Studies in rats and mice with oral doses many times the recommended human dose showed no evidence of carcinogenicity.

Studies in rats and rabbits with oral doses up to 300 and 55 times the human dose, respectively, have not shown that nizatidine impairs fertility.

Rabbits treated with a dose equivalent to 300 times the human dose had abortions, a decreased number of live fetuses, and depressed fetal weights.

Nizatidine is distributed into milk in rats, and growth depression has occurred in the offspring of lactating rats treated with the drug.

For more Non-Human Toxicity Excerpts (Complete) data for NIZATIDINE (9 total), please visit the HSDB record page.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
USGS Health-Based Screening Levels for Evaluating Water-Quality · 3 件

Nizatidine

Pharmaceutical

Smith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Nizatidine

3.5

14.8

The recommended oral dosage for adults is 150 mg once daily at bedtime.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 150 mg/day, Lowest Therapeutic Dose (LTD): 1.9 mg/kg-day, and Screening Dose: 0.0006 mg/kg-day.

31-Mar-16

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
3
rtecs
KM6565000
毒性
LD50 in mice, rats (mg/kg): 265, >300 i.v.; 1685, 1680 orally (Pioch)
hs_code
29349990
risk_code
22
hazard_code
Xn
safety_code
36
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids
有毒物質データの
76963-41-2(Hazardous Substances Data)
· 6 件

P41PML4GHR

NIZATIDINE

Mechanisms of Action [MoA] - Histamine H2 Receptor Antagonists

Established Pharmacologic Class [EPC] - Histamine-2 Receptor Antagonist

Nizatidine is a Histamine-2 Receptor Antagonist. The mechanism of action of nizatidine is as a Histamine H2 Receptor Antagonist.

NIZATIDINE

MeSH Pharmacological Classification · 2 件

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.

Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.

Absorption, Distribution and Excretion · 6 件

Rapid (bioavailability of nizatidine exceeds 70%)

0.8 to 1.5 L/kg

40-60 L/h

Nizatidine has a duration of action of up to 10 hours. It is eliminated primarily by the kidneys; 90% of the administered dose (65% as unchanged drug) is recovered in the urine within 16 hours.

Distribution of nizatidine into human body tissues and fluids has not been fully characterized. The apparent volume of distribution of the drug is reported to be 0.8-1.5 l/kg in adults and does not appear to be altered substantially in patients with renal dysfunction.

In one study, the oral bioavailability of nizatidine exceeded 70% and was not affected by food or the anticholinergic drug, propantheline. Its apparent volume of distribution is 1.2 l/kg. Systemic clearance (10 ml/min/kg) is decreased in uremic patients and in the elderly.

用途と製造

UsesMEDICATION
Methods of ManufacturingRP Pioch, Eur Pat Appl 49618; Idem, US Pat 4,375547 (1982, 1983 both to Eli Lilly)
Formulations/PreparationsEach Pulvule (capsule) contains for oral administration gelatin, pregelatinized starch, silicone, titanium dioxide, yellow iron oxide and 150 mg or 300 mg nizatidine.
応用分野 · 4 件

用途ヒスタミンH2 受容体遮断剤 です。胃粘膜のヒスタミンH2受容体を遮断し、 胃酸分泌を抑制作用を示します。

説明Nizatidine is the fifth H2-antagonist introduced to the world market as an antiulcer agent. It is reported to be effective in the treatment of both duodenal and gastric ulcers or the prevention of their recurrences. Given once-daily, nizatidine’s bioavailability is not diminished by the concurrent administration of an antacid.

使用Nizatidine is used for treating stomach and duodenum ulcers and other conditions accompanied by elevated acidity of the gastrointestinal tract.

一般的な説明Nizatidine, N-[2-[[[2-(dimethylamino)methyl]-4-thiazolyl]methyl]thio]-ethyl]-N'-methyl-2-nitro-1,1-ethenediamine (Axid), is an off-white to buff crystallinesolid that is soluble in water, alcohol, and chloroform. It isa thaizole derivative of raniditine and has pKas of 2.1 (side chain) and 6.8 (dimethylamino). Nizatidine’s mechanism ofaction is similar to other H2-antagonists, as is its receptor selectivity.It is more potent than cimetidine.Nizatidine has excellent oral bioavailability (>90%).The effects of antacids or food on its bioavailability arenot clinically significant. The elimination half-life is 1 to2 hours. It is excreted primarily in the urine (90%) andmostly as unchanged drug (60%). Metabolites include nizatidinesulfoxide (6%), N-desmethylnizatidine (7%), andnizatidine N-oxide (dimethylaminomethyl function).Nizatidine has no demonstrable antiandrogenic action, effectson other hormones, or inhibitory effects on cytochromeisozymes involved in the metabolism of other drugs.

上流・下流製品情報

上流原料

ジヒドリド硫黄DimethylamineEエチレンジアミン (無水)ニトロメタン1,3-ジクロロ-2-プロパノン2-Dimethylaminomethyl-4-Chloromethyl-4-hydrony thiazolineチアゾリジン2,4-ジアミノアゾベンゼン·塩酸塩Dimethyl aminothic acetamide1-ビニルピレンDimethyl amino acetenitrile酢酸エチル2-Dimethyl amino methyl-4-chloro methyl thiazole HClメタノールAnhydrous pyridineシクロヘキサノン1,1-ビス(メチルチオ)-2-ニトロエチレンヨードメタンシアン化カリウム1-アミノエタノールメチルアミン2-(ニトロメチレン)チアゾリジン

補足説明

定義ChEBI: A member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4.